{"id":"NCT01282073","sponsor":"Kyungpook National University Hospital","briefTitle":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","officialTitle":"A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2016-05","completion":"2016-05","firstPosted":"2011-01-24","resultsPosted":"2025-08-27","lastUpdate":"2025-08-27"},"enrollment":43,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glomerulonephritis, Membranous"],"interventions":[{"type":"DRUG","name":"Mycophenolate mofetil, low dose steroid","otherNames":["Myconol, MMF"]},{"type":"DRUG","name":"Cyclosporin, low dose steroid","otherNames":["Implanta soft capsule"]}],"arms":[{"label":"Mycophenolate mofetil, low dose steroid","type":"EXPERIMENTAL"},{"label":"Cyclosporin, low dose steroid","type":"ACTIVE_COMPARATOR"}],"summary":"Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.","primaryOutcome":{"measure":"Percentage of Complete Remission","timeFrame":"at 48 week after treatment","effectByArm":[{"arm":"Mycophenolate Mofetil, Low Dose Steroid","deltaMin":4,"sd":null},{"arm":"Cyclosporin, Low Dose Steroid","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["South Korea"]},"refs":{"pmids":["34778952","29441742"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Upper respiratory infection","Epigastric discomfort","Diarrhea","Skin infection","Anaemia"]}}